Evaluation of Empagliflozin vs Standard Care in Veterans With Prediabetes

Summary

Prediabetes effects 96 million people 18 years of age or older. It is important to identify treatment options to slow or prevent progression to diabetes. It is also critical to assess the potential of medications like sodium glucose transporter 2 inhibitors to reduce the risk of cardiovascular events and kidney complications, both common and costly complications of diabetes. This is a 12-week, open-label pilot feasibility study assessing the use of empagliflozin in prediabetes.

Timeline

Start

2024-12-06

Primary completion

2025-09-05

Completion

2025-09-05

Drugs

Indications